| __timestamp | BioCryst Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 101881000 |
| Thursday, January 1, 2015 | 1896000 | 4011000 |
| Friday, January 1, 2016 | 2699000 | 102026000 |
| Sunday, January 1, 2017 | 1702000 | 96171000 |
| Monday, January 1, 2018 | 471000 | 66449000 |
| Tuesday, January 1, 2019 | 4101000 | 42672000 |
| Wednesday, January 1, 2020 | 1676000 | 42534000 |
| Friday, January 1, 2021 | 7264000 | 3068000 |
| Saturday, January 1, 2022 | 6594000 | 1400000 |
| Sunday, January 1, 2023 | 4661000 | 3008000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for Celldex Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Celldex's cost of revenue has seen significant fluctuations, peaking in 2016 with a staggering 102 million, while BioCryst's costs remained relatively stable, with a notable increase in 2021, reaching 7.3 million.
Celldex's cost of revenue in 2014 was nearly 840 times that of BioCryst, highlighting a stark contrast in their operational scales. However, by 2023, the gap narrowed significantly, with Celldex's costs only about 65% higher than BioCryst's. This shift underscores the dynamic nature of the biotech industry, where strategic pivots and market conditions can dramatically alter financial landscapes.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs BioCryst Pharmaceuticals, Inc.
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored